Seth Loring Harrison
CIK 1404955 · last filed 2026-06-05
Seth Loring Harrison is a corporate insider who has filed 69 SEC Form 4 insider transactions across 4 companies since 2010. The most recent filing, for STOK, was dated Jun 5, 2026. Across all open-market trades the lifetime net is −$52.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $511.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$511.76M
4
69
-$52.02M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| STOK | Director | 17,161,713 | $29.82 | $511.76M | $39.63M | 10 | 2026-06-05 |
| Akero Therapeutics, Inc. (AKRO) Delisted | Director | 0 | $54.65 | $0 | $14.28M | 13 | 2025-12-09 |
| HeartWare International, Inc. (HTWR) Delisted | Director | 0 | — | — | -$111.36M | 31 | 2016-08-24 |
| Eledon Pharmaceuticals, Inc. (TKAI) Delisted | Director | 8,124,773 | — | — | $5.44M | 3 | 2016-06-16 |
Recent Filings
69 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-05 | STOK | Grant (A) | — | $0 | EDGAR |
| 2025-12-09 | Akero Therapeutics, Inc. (AKRO) Delisted | Disp (D) | −293,762 | $0 | EDGAR |
| 2025-06-05 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | +9,398 | $0 | EDGAR |
| 2025-06-04 | STOK | Grant (A) | — | $0 | EDGAR |
| 2024-06-11 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | STOK | Grant (A) | — | $0 | EDGAR |
| 2023-06-27 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-15 | STOK | Grant (A) | — | $0 | EDGAR |
| 2022-12-02 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −23,131 | -$1.09M | EDGAR |
| 2022-11-01 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −44,103 | -$1.78M | EDGAR |